uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies

uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies

GERMANTOWN, MD / ACCESS Newswire / March 30, 2026 / uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development, today announced a strategic partnership with Cellinfinity BIO, a biotechnology company developing…

uBriGene, Cellinfinity BIO join hands to accelerate in vivo CAR-T therapies

The partnership focuses on progressing Cellinfinity BIO’s programmes CIB-301 and CIB-350. uBriGene’s LVV Turbo platform will provide good manufacturing practice (GMP) lentiviral vector manufacturing, production, process development, and The post uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies appeared first on Pharmaceutical Business review.

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

uBriGene Biosciences has partnered with Cellinfinity BIO to advance the clinical development of in vivo CAR-T therapy programmes for haematologic and solid tumours.The post uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies appeared first on Hospital Management.